Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV001055165 | SCV001219539 | likely pathogenic | Glycogen storage disease, type II | 2019-01-29 | criteria provided, single submitter | clinical testing | In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. Donor and acceptor splice site variants typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in GAA are known to be pathogenic (PMID: 18425781, 22252923). Another variant affecting this splice site, c.1754+1G>A, has been reported in combination with a second variant in an individual with Pompe disease. This variant is not present in population databases (ExAC no frequency). This sequence change affects a donor splice site in intron 12 of the GAA gene. It is expected to disrupt RNA splicing and likely results in an absent or disrupted protein product. |